Cambridge today (23 June) begins a three-day celebration of the wonders of the brain, with talks, hands-on activities and a ‘secret cinema’ – all part of Cambridge BRAINFest 2017, a free public festival celebrating the most complex organ in the body.
Why are we getting so fat? Why do teenagers really need to lie-in? And can we fix a broken brain? These are just some of the questions that will be answered at Cambridge BRAINFest 2017, a free public festival celebrating the most complex organ in the body.
Is drug addiction hereditary? Why do emotions dominate our earliest memories? Are robots a threat to humanity? These were just some of the thorny questions posed by A-Level students to Cambridge neuroscientists at a recent outreach event organised with the David Ross Educational Trust.
Last month, the Medicines and Healthcare products Regulatory Agency announced the UK’s biggest ever single seizure of smart drugs, also known as cognitive enhancers. With over 20,000 units, of 13 different types of cognitive enhancement medicines, the seizure represents an approximate value of £200,000. Here, Professor Barbara Sahakian from the Department of Psychiatry discusses the implications. This article first appeared on The Conversation website on 31 October 2014.
Scientists in Cambridge have found hidden signatures in the brains of people in a vegetative state, which point to networks that could support consciousness even when a patient appears to be unconscious and unresponsive. The study could help doctors identify patients who are aware despite being unable to communicate.
AstraZeneca, its global biologics research and development arm, MedImmune, and the University of Cambridge today announce four new collaborations, building on their existing partnership. The latest collaborations reinforce AstraZeneca’s commitment to research in Cambridge following the company’s decision to locate one of its three global R&D centres and its global headquarters in the city that has been home to MedImmune’s biologics research laboratories for 25 years.
A new drug based on decades of research at the University of Cambridge has today been approved by the National Institute for Health and Care Excellence (NICE) for use in people with relapsing-remitting multiple sclerosis. Clinical trials have shown that Alemtuzumab, marketed under the name Lemtrada, reduces disease activity, limits the accumulation of further disability over time and may even allow some existing damage to recover.